Protein kinase inhibitors

LianBio Appoints Pascal Qian as General Manager of China

Retrieved on: 
Monday, August 2, 2021
Health, Biotechnology, Chemical compounds, Organic compounds, Aminopyridines, Thioethers, Chloroarenes, Specialty drugs, Protein kinase inhibitors, Palbociclib, Sunitinib, Axitinib, Crizotinib, Qian

LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced that it has appointed Pascal Qian to the position of China General Manager.

Key Points: 
  • LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced that it has appointed Pascal Qian to the position of China General Manager.
  • Mr. Qian has extensive experience launching products in China, including Verzenio, Tyvyt, Elunate, Afinitor, Votrient, Sutent, Vfend and Singulair.
  • He has also led new product development initiatives in China for multiple globally developed drugs, including crizotinib, axitinib and palbociclib.
  • Mr. Qian most recently served as the Vice President, Head of Oncology Business Unit, at Lilly China.

Ribon Therapeutics Announces Publication in Cancer Cell of Pre-Clinical and Mechanism of Action Data for RBN-2397

Retrieved on: 
Thursday, July 22, 2021
Communications, Health, Clinical trials, Publishing, Pharmaceutical, Biotechnology, Lung cancer, Cancer, Non-small-cell lung carcinoma, Protein kinase inhibitors, Clinical medicine, Medicine, Health, Tyrosine kinase receptors, Cancer immunotherapy, RBN-2397, Ribon Therapeutics, RBN-2397, RIBON THERAPEUTICS

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced the first publication in the peer-reviewed journal, Cancer Cell, of preclinical data from its lead asset, RBN-2397, a small molecule inhibitor of PARP7.

Key Points: 
  • Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced the first publication in the peer-reviewed journal, Cancer Cell, of preclinical data from its lead asset, RBN-2397, a small molecule inhibitor of PARP7.
  • PARP7 is overexpressed in a number of tumors, including squamous cell carcinoma of the lung (SCCL), which represents approximately 30% of all non-small cell lung cancers.
  • PARP7 is the first monoPARP to be targeted therapeutically and RBN-2397 is the first potent and selective PARP7 inhibitor to enter clinical development.
  • Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.

FDA lifts Partial Clinical Hold on Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Retrieved on: 
Wednesday, July 14, 2021
Enzymes, Chemical compounds, Branches of biology, Tyrosine kinase receptors, Leukemia, Protein kinase inhibitors, CD135, Cyclin-dependent kinase 8, Tumors of the hematopoietic and lymphoid tissues, Acute myeloid leukemia, Myeloid leukemia, Clonal hypereosinophilia

Following the completion ofthe75mg cohort, the data generated will be reviewed by the agency and a further dose escalation strategy will be established.

Key Points: 
  • Following the completion ofthe75mg cohort, the data generated will be reviewed by the agency and a further dose escalation strategy will be established.
  • The partial clinical hold was issued following Ryvu's recent report to the FDA of a Serious Adverse Event (SAE) involving a patient death that may possibly be related to RVU120.
  • RVU120 is a selective CDK8/CDK19 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors currently in Phase 1b clinical development for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
  • SEL24 (MEN1703) is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group, currently in Phase II clinical studies in acute myeloid leukemia.

TRIO Completes Enrolment for Phase 2 Giredestrant Early Breast Cancer Trial Ahead of Schedule

Retrieved on: 
Tuesday, July 6, 2021
Chemical compounds, Organic compounds, Drugs, Protein kinase inhibitors, Breakthrough therapy, Piperazines, Cyclopentanes, Lactams, Palbociclib, Breast cancer, Conjugated estrogens, Cancer research

The trial is investigating the ability to expand the safety and efficacy of giredestrant as monotherapy and in combination with palbociclib into the early breast cancer setting.

Key Points: 
  • The trial is investigating the ability to expand the safety and efficacy of giredestrant as monotherapy and in combination with palbociclib into the early breast cancer setting.
  • The trial design evaluates the efficacy, safety, and pharmacokinetics of presurgical treatment with giredestrant plus palbociclib compared with anastrozole plus palbociclib for postmenopausal women with ER+ and HER2-negative untreated early breast cancer.
  • The scale of interest from patients further underlines the urgency to bring forward new treatment options to treat early stage breast cancer.
  • TRIO advances translational cancer research by introducing innovative and novel targeted therapeutic concepts into the clinical trial setting.

Aurora Kinase Inhibitor Pipeline Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 6, 2021
Health, Pharmaceutical, Protein kinase inhibitors, Aurora kinase, Pipeline, Aurora inhibitor

The "Aurora Kinase Inhibitor - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Aurora Kinase Inhibitor - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Aurora Kinase Inhibitor - Pipeline Insight, 2021" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Aurora Kinase Inhibitor pipeline landscape.
  • This segment of the report provides insights about the different Aurora Kinase Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Aurora Kinase Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Global Kinase Inhibitors Market Report 2021: Data from 2019, 2020 Estimates for 2021 and Projections of CAGRs Through 2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 1, 2021
Biotechnology, Pharmaceutical, Health, Protein kinase inhibitors, Lactams, Tyrosine kinase inhibitors, Drugs, Morpholines, Enzyme inhibitors

The global market for kinase inhibitors should grow from $57.6 billion in 2021 to $79.2 billion by 2026 with a compound annual growth rate (CAGR) of 6.6% for the period of 2021-2026.

Key Points: 
  • The global market for kinase inhibitors should grow from $57.6 billion in 2021 to $79.2 billion by 2026 with a compound annual growth rate (CAGR) of 6.6% for the period of 2021-2026.
  • This report is designed to be a business tool that will provide a thorough evaluation of the markets for kinase inhibitors.
  • Various types of kinase inhibitors have been analyzed in the report, and along with their different application scenarios, the scope of this study includes regulatory aspects, pipeline analysis and demand for kinase inhibitors.
  • The market for kinase inhibitor market is experiencing an increasing demand for a number of novel kinase inhibitors being utilized in human trials.

Angion Announces Results from the Phase 2 ALI-201 Study in Patients with COVID-19 Associated Pneumonia

Retrieved on: 
Tuesday, June 29, 2021
Branches of biology, Biology, MTOR, Signal transduction, Tyrosine kinase receptors, Lactams, Protein kinase inhibitors

The adverse events and overall safety of the trial were consistent with previously published reports in patients hospitalized with severe COVID-19 pneumonia.

Key Points: 
  • The adverse events and overall safety of the trial were consistent with previously published reports in patients hospitalized with severe COVID-19 pneumonia.
  • In contrast, patients in our ongoing trials receive ANG-3777 within 1-3 days after the targeted organ injury.
  • Angion is also currently evaluating ANG-3070, a tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in Phase 1.
  • Angion undertakes no obligation to update any forward-looking statement in this press release, except as required by law.

Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer

Retrieved on: 
Thursday, June 17, 2021
Health sciences, Health, Drugs, Breakthrough therapy, Orphan drugs, Protein kinase inhibitors, Infectious causes of cancer, c-Met inhibitor, Cancer research, Stomach cancer, ALK inhibitor, ROS1

We are pleased to receive this designation for TPX-0022 as we work to develop it as a potentially differentiated option for patients affected by MET-driven gastric cancer.

Key Points: 
  • We are pleased to receive this designation for TPX-0022 as we work to develop it as a potentially differentiated option for patients affected by MET-driven gastric cancer.
  • There are currently no approved MET inhibitors for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma.
  • Orphan Drug Designation is granted by the FDA to assist in the development of drug candidates that may offer therapeutic benefits for diseases with a prevalence of fewer than 200,000 patients annually.
  • The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.

Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting

Retrieved on: 
Friday, June 11, 2021
Chemical compounds, Tyrosine kinase receptors, Protein kinase inhibitors, Organic compounds, AXL receptor tyrosine kinase, Heterocyclic compounds, Bemcentinib, Orphan drugs, CD135, Midostaurin

An update will be provided from an expansion cohort of 27 relapsed/refractory AML patients, who were assessed to explore safety and efficacy together with translational analysis.

Key Points: 
  • An update will be provided from an expansion cohort of 27 relapsed/refractory AML patients, who were assessed to explore safety and efficacy together with translational analysis.
  • The data indicate that the combination of bemcentinib, a once-daily oral AXL-inhibitor and LDAC is efficacious and well tolerated in the elderly and unfit relapsed AML population.
  • Ongoing dialogue continues with the FDA and EMA regulatory agenciesto align on a pathway for apivotalregistration trial for the combination ofbemcentinibandLDAC in relapsed elderly AML patients unfit for intensive chemotherapy.
  • Data from a Phase II in human clinical trial has shown that treatment with AXL inhibitor bemcentinib increased the rate ventilator free survival in hospitalised COVID-19 patients.

Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting

Retrieved on: 
Friday, June 11, 2021
Chemical compounds, Tyrosine kinase receptors, Protein kinase inhibitors, Organic compounds, AXL receptor tyrosine kinase, Heterocyclic compounds, Bemcentinib, Orphan drugs, CD135, Midostaurin

An update will be provided from an expansion cohort of 27 relapsed/refractory AML patients, who were assessed to explore safety and efficacy together with translational analysis.

Key Points: 
  • An update will be provided from an expansion cohort of 27 relapsed/refractory AML patients, who were assessed to explore safety and efficacy together with translational analysis.
  • The data indicate that the combination of bemcentinib, a once-daily oral AXL-inhibitor and LDAC is efficacious and well tolerated in the elderly and unfit relapsed AML population.
  • Ongoing dialogue continues with the FDA and EMA regulatory agenciesto align on a pathway for apivotalregistration trial for the combination ofbemcentinibandLDAC in relapsed elderly AML patients unfit for intensive chemotherapy.
  • Data from a Phase II in human clinical trial has shown that treatment with AXL inhibitor bemcentinib increased the rate ventilator free survival in hospitalised COVID-19 patients.